Page 1 of 41
BARKLEY-STYLE PMHNP REVIEW EXAM 2026/2027
COMPLETE (100) CURRENT TESTING QUESTIONS AND
CORRECT ANSWERS WITH DETAILED RATIONALES.
PMHNP
Prepare for the Barkley-Style PMHNP Review Exam with a focused study resource
covering essential concepts in psychiatric-mental health nurse practitioner practice.
It supports review of psychiatric assessment, differential diagnosis,
psychopharmacology, therapeutic approaches, patient management, and clinical
decision-making. Use the material to reinforce key knowledge, strengthen clinical
reasoning, and identify areas that may require additional review before certification
testing. This resource is best suited for PMHNP students and nurse practitioner
certification candidates preparing for psychiatric-mental health board examinations.
MULTIPLE CHOICE.
SECTION 1: NEUROBIOLOGY & PSYCHOPHARMACOLOGY (Questions 1-25)
1. A patient on long-term haloperidol presents with parkinsonism,
including bradykinesia and rigidity. This adverse effect is primarily caused
by blockade of dopamine receptors in which brain pathway?
a) Mesolimbic pathway
b) Mesocortical pathway
c) Nigrostriatal pathway
d) Tuberoinfundibular pathway
Answer: c) Nigrostriatal pathway
Rationale: The nigrostriatal pathway (substantia nigra to striatum) is
responsible for motor control. Dopamine blockade in this pathway causes
extrapyramidal symptoms (EPS) including parkinsonism (bradykinesia, rigidity,
tremor), dystonia, and akathisia. The mesolimbic pathway is involved in
positive symptoms of psychosis; the mesocortical pathway is involved in
negative symptoms and cognition; and the tuberoinfundibular pathway
regulates prolactin release.
, Page 2 of 41
2. Which neurotransmitter is primarily implicated in the pathophysiology
of obsessive-compulsive disorder (OCD)?
a) Dopamine
b) Serotonin
c) Norepinephrine
d) Glutamate
Answer: b) Serotonin
Rationale: The serotonin system is the primary neurotransmitter implicated in
OCD pathophysiology. This is supported by the efficacy of SSRIs in treating
OCD symptoms. Dysregulation of serotonin pathways in the orbitofrontal
cortex, anterior cingulate cortex, and striatum is believed to contribute to
obsessions and compulsions. Glutamate and dopamine also play roles, but
serotonin is the primary target.
3. Which neurotransmitter is most closely associated with the regulation
of mood, appetite, and sleep, and is often targeted in the treatment of
depression?
a) Dopamine
b) Norepinephrine
c) Serotonin
d) Acetylcholine
Answer: c) Serotonin
Rationale: Serotonin (5-HT) regulates mood, appetite, sleep, and impulse
control. It is the primary neurotransmitter targeted by SSRIs and SNRIs in the
treatment of depression and anxiety disorders. Dopamine is more associated
with reward and motivation, norepinephrine with arousal and attention, and
acetylcholine with memory and cognition.
4. A patient is started on fluoxetine for depression. The PMHNP explains
that the therapeutic effect of SSRIs is primarily due to:
a) Blockade of dopamine reuptake
b) Inhibition of serotonin reuptake at the synaptic cleft
c) Antagonism of serotonin receptors
, Page 3 of 41
d) Enhancement of GABA activity
Answer: b) Inhibition of serotonin reuptake at the synaptic cleft
Rationale: SSRIs (selective serotonin reuptake inhibitors) work by blocking
the serotonin transporter (SERT), which inhibits the reuptake of serotonin from
the synaptic cleft, increasing serotonin availability at postsynaptic receptors.
This mechanism is responsible for their antidepressant and anxiolytic effects.
5. A patient is prescribed aripiprazole (Abilify). The PMHNP understands
that this medication works as a:
a) Full dopamine antagonist
b) Partial dopamine agonist
c) Full serotonin agonist
d) Anticholinergic agent
Answer: b) Partial dopamine agonist
Rationale: Aripiprazole is a partial dopamine agonist at D2 receptors. It acts
as a partial agonist, stabilizing dopamine activity—reducing it when it is
excessive (positive symptoms) and increasing it when it is deficient (negative
symptoms and cognition). This mechanism is unique among atypical
antipsychotics and contributes to its lower EPS risk.
6. A patient with bipolar disorder is started on lithium. The PMHNP should
monitor which laboratory values at baseline and periodically?
a) Complete blood count and liver function tests
b) Thyroid function tests and renal function tests
c) Hemoglobin A1c and lipid panel
d) Serum electrolytes and uric acid
Answer: b) Thyroid function tests and renal function tests
Rationale: Lithium can cause hypothyroidism and nephrogenic diabetes
insipidus. Baseline and periodic monitoring of thyroid function (TSH) and renal
function (BUN, creatinine) is essential. Lithium is excreted renally, and
impaired renal function increases the risk of toxicity.
, Page 4 of 41
7. The therapeutic serum lithium level for acute mania is:
a) 0.4-0.8 mEq/L
b) 0.6-1.2 mEq/L
c) 0.8-1.5 mEq/L
d) 1.5-2.0 mEq/L
Answer: c) 0.8-1.5 mEq/L
Rationale: The therapeutic range for lithium in acute mania is 0.8-1.5 mEq/L.
For maintenance therapy, the target is typically 0.6-1.2 mEq/L. Levels above
1.5 mEq/L indicate toxicity, and levels below 0.6 mEq/L are generally
subtherapeutic.
8. A patient prescribed clozapine (Clozaril) develops a fever and sore
throat. Which laboratory value should the PMHNP prioritize?
a) Serum creatinine
b) White blood cell count with differential
c) Liver function tests
d) Serum potassium
Answer: b) White blood cell count with differential
Rationale: Clozapine carries a risk of agranulocytosis (severe neutropenia),
which can be fatal. Fever and sore throat may be early signs of
agranulocytosis. Regular WBC and absolute neutrophil count (ANC)
monitoring is required through the REMS program. The medication should be
held, and the provider should be notified immediately.
9. Which of the following antipsychotics is most associated with
significant weight gain and metabolic syndrome?
a) Aripiprazole (Abilify)
b) Ziprasidone (Geodon)
c) Olanzapine (Zyprexa)
d) Lurasidone (Latuda)
Answer: c) Olanzapine (Zyprexa)
Rationale: Olanzapine has the highest risk of weight gain and metabolic side
effects among atypical antipsychotics. Patients can gain significant weight
BARKLEY-STYLE PMHNP REVIEW EXAM 2026/2027
COMPLETE (100) CURRENT TESTING QUESTIONS AND
CORRECT ANSWERS WITH DETAILED RATIONALES.
PMHNP
Prepare for the Barkley-Style PMHNP Review Exam with a focused study resource
covering essential concepts in psychiatric-mental health nurse practitioner practice.
It supports review of psychiatric assessment, differential diagnosis,
psychopharmacology, therapeutic approaches, patient management, and clinical
decision-making. Use the material to reinforce key knowledge, strengthen clinical
reasoning, and identify areas that may require additional review before certification
testing. This resource is best suited for PMHNP students and nurse practitioner
certification candidates preparing for psychiatric-mental health board examinations.
MULTIPLE CHOICE.
SECTION 1: NEUROBIOLOGY & PSYCHOPHARMACOLOGY (Questions 1-25)
1. A patient on long-term haloperidol presents with parkinsonism,
including bradykinesia and rigidity. This adverse effect is primarily caused
by blockade of dopamine receptors in which brain pathway?
a) Mesolimbic pathway
b) Mesocortical pathway
c) Nigrostriatal pathway
d) Tuberoinfundibular pathway
Answer: c) Nigrostriatal pathway
Rationale: The nigrostriatal pathway (substantia nigra to striatum) is
responsible for motor control. Dopamine blockade in this pathway causes
extrapyramidal symptoms (EPS) including parkinsonism (bradykinesia, rigidity,
tremor), dystonia, and akathisia. The mesolimbic pathway is involved in
positive symptoms of psychosis; the mesocortical pathway is involved in
negative symptoms and cognition; and the tuberoinfundibular pathway
regulates prolactin release.
, Page 2 of 41
2. Which neurotransmitter is primarily implicated in the pathophysiology
of obsessive-compulsive disorder (OCD)?
a) Dopamine
b) Serotonin
c) Norepinephrine
d) Glutamate
Answer: b) Serotonin
Rationale: The serotonin system is the primary neurotransmitter implicated in
OCD pathophysiology. This is supported by the efficacy of SSRIs in treating
OCD symptoms. Dysregulation of serotonin pathways in the orbitofrontal
cortex, anterior cingulate cortex, and striatum is believed to contribute to
obsessions and compulsions. Glutamate and dopamine also play roles, but
serotonin is the primary target.
3. Which neurotransmitter is most closely associated with the regulation
of mood, appetite, and sleep, and is often targeted in the treatment of
depression?
a) Dopamine
b) Norepinephrine
c) Serotonin
d) Acetylcholine
Answer: c) Serotonin
Rationale: Serotonin (5-HT) regulates mood, appetite, sleep, and impulse
control. It is the primary neurotransmitter targeted by SSRIs and SNRIs in the
treatment of depression and anxiety disorders. Dopamine is more associated
with reward and motivation, norepinephrine with arousal and attention, and
acetylcholine with memory and cognition.
4. A patient is started on fluoxetine for depression. The PMHNP explains
that the therapeutic effect of SSRIs is primarily due to:
a) Blockade of dopamine reuptake
b) Inhibition of serotonin reuptake at the synaptic cleft
c) Antagonism of serotonin receptors
, Page 3 of 41
d) Enhancement of GABA activity
Answer: b) Inhibition of serotonin reuptake at the synaptic cleft
Rationale: SSRIs (selective serotonin reuptake inhibitors) work by blocking
the serotonin transporter (SERT), which inhibits the reuptake of serotonin from
the synaptic cleft, increasing serotonin availability at postsynaptic receptors.
This mechanism is responsible for their antidepressant and anxiolytic effects.
5. A patient is prescribed aripiprazole (Abilify). The PMHNP understands
that this medication works as a:
a) Full dopamine antagonist
b) Partial dopamine agonist
c) Full serotonin agonist
d) Anticholinergic agent
Answer: b) Partial dopamine agonist
Rationale: Aripiprazole is a partial dopamine agonist at D2 receptors. It acts
as a partial agonist, stabilizing dopamine activity—reducing it when it is
excessive (positive symptoms) and increasing it when it is deficient (negative
symptoms and cognition). This mechanism is unique among atypical
antipsychotics and contributes to its lower EPS risk.
6. A patient with bipolar disorder is started on lithium. The PMHNP should
monitor which laboratory values at baseline and periodically?
a) Complete blood count and liver function tests
b) Thyroid function tests and renal function tests
c) Hemoglobin A1c and lipid panel
d) Serum electrolytes and uric acid
Answer: b) Thyroid function tests and renal function tests
Rationale: Lithium can cause hypothyroidism and nephrogenic diabetes
insipidus. Baseline and periodic monitoring of thyroid function (TSH) and renal
function (BUN, creatinine) is essential. Lithium is excreted renally, and
impaired renal function increases the risk of toxicity.
, Page 4 of 41
7. The therapeutic serum lithium level for acute mania is:
a) 0.4-0.8 mEq/L
b) 0.6-1.2 mEq/L
c) 0.8-1.5 mEq/L
d) 1.5-2.0 mEq/L
Answer: c) 0.8-1.5 mEq/L
Rationale: The therapeutic range for lithium in acute mania is 0.8-1.5 mEq/L.
For maintenance therapy, the target is typically 0.6-1.2 mEq/L. Levels above
1.5 mEq/L indicate toxicity, and levels below 0.6 mEq/L are generally
subtherapeutic.
8. A patient prescribed clozapine (Clozaril) develops a fever and sore
throat. Which laboratory value should the PMHNP prioritize?
a) Serum creatinine
b) White blood cell count with differential
c) Liver function tests
d) Serum potassium
Answer: b) White blood cell count with differential
Rationale: Clozapine carries a risk of agranulocytosis (severe neutropenia),
which can be fatal. Fever and sore throat may be early signs of
agranulocytosis. Regular WBC and absolute neutrophil count (ANC)
monitoring is required through the REMS program. The medication should be
held, and the provider should be notified immediately.
9. Which of the following antipsychotics is most associated with
significant weight gain and metabolic syndrome?
a) Aripiprazole (Abilify)
b) Ziprasidone (Geodon)
c) Olanzapine (Zyprexa)
d) Lurasidone (Latuda)
Answer: c) Olanzapine (Zyprexa)
Rationale: Olanzapine has the highest risk of weight gain and metabolic side
effects among atypical antipsychotics. Patients can gain significant weight
